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Current Tax Laws 
and R & D
Opportunity and Incentive
By Mary Lynn Siegler
The Economic Recovery Act has 
made many changes to the current tax 
laws. One such change was the addi­
tion of a credit against tax for research 
expenses made after June 30, 1981 
and before January 1, 1986. This new 
law (Section 44F) was designed to en­
courage companies to perform more 
research and development. As a result 
of this encouragement, many com­
panies are consulting their account­
ants to find out how they can benefit 
from the research credit. One such in­
quiry is described below.
Corporation X has decided to spend 
a portion of the company’s profits on 
research and development (R&D). 
They do not have the inhouse facilities 
with which to perform the needed 
research and therefore find it neces­
sary to contract for these services.
A 78 percent stockholder (E) of Cor­
poration X has proposed that he form 
a partnership with N and that the E-N 
Partnership perform the needed R&D 
for X Corporation. N is an engineer and 
has experience in the R&D field.
Because E&N do not have the 
money to fund the needed R&D on 
their own, X Corporation will sign a 
contract with E-N which stipulates that 
X make regular payments to E-N in 
return for the first right to purchase any 
patents obtained by E-N as a result of 
the R&D performed for X.
X Corporation wants to know what 
the tax consequences of this plan 
would be and what changes to the plan 
could be made in order to lower the 
taxes of both Corporation X and Part­
nership E-N.
Section 44F—Credit for Research 
Activities
To answer these questions, Code 
Section 44F was researched first. This 
section allows as a credit against tax;
“an amount equal to 25% of the ex­
cess (if any) of—
(1) the qualified research expenses 
for the taxable year, over
(2) the base period research ex­
penses.” (Sec. 44F(a))
Qualified research expenses are ex­
penses paid or incurred by the tax­
payer while carrying on any trade or 
business for in-house research and 
contract research expenses. (Sec. 
44F(b)) However, there are certain 
restrictions on amounts paid for con­
tract research as follows:
(1) Only 65% of amounts paid for 
contract research expenses are 
considered qualified research 
expenses for the purpose of 
calculating the credit. (Sec. 
44F(b))
(2) Amounts paid to others for R&D 
qualify for the credit only if they 
are pursuant to a written re­
search agreement between the 
parties. (Sec. 44F(e))
(3) The organization performing the 
contract research must, accord­
ing to Sec. 44F(e), be;
(a) any educational organization 
which is described in section 
170(b) (1) (A) (ii) and which 
is an institution of higher 
education (as defined in sec­
tion 3304(f), or
(b) any other organization 
which—
(i) is described in section 
501(c) (3) and exempt 
from tax under section 
501(a).
(ii) is organized and oper­
ated primarily to con­
duct scientific research, 
and
(iii) is not a private founda­
tion.
Therefore, it would appear from ex­
amining Section 44F that X Corpora­
tion would be allowed to use 65 
percent of the amount it pays to E-N 
Partnership in calculating the tax credit 
as long as Corp. X has a written re­
search agreement with E-N.
In order to obtain a credit, X must 
have expenses during the taxable year 
which exceed the base period re­
search expenses. The base period 
research expenses are arrived at by 
taking the qualified research expenses 
for the three immediately preceding 
tax years and averaging them. Special 
rules apply to calculating the base 
period research expenses when the 
credit is taken for years beginning in 
1980-1982. (Sec. 44F(c)) In no event 
shall the base period research ex­
penses be less than 50 percent of the 
qualified research expenses for the 
determination year. (Sec. 44F(c))
This translates to a maximum credit 
of 8.125 percent of qualified research 
expenditures of X Corp., as shown in 
the following computation.
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Payments to E-N Partnership 100
Amount allowable for 
contract services 65%
Qualified research expenses 65
Minimum base period re­




In addition, the credit is limited to the 
tax liability for the taxable year reduced 
by other credits. However, it may be car­
ried back three and forward 15 years. 
(Sec. 44F(g))
The credit is only available for expen­
ditures made after June 30, 1981 and 
before January 1, 1986.
Section 44F has one other restriction 
applicable to X Corp. which is spelled 
out in the Committee Reports on the 
Economic Recovery Act.1
‘‘The credit is not available for any 
activity performed for another person 
(or governmental entity), whether pur­
suant to a grant, contract, or otherwise. 
Thus, if a taxpayer contracts with a re­
search firm, university, or other person 
for research to be performed on the 
taxpayer’s behalf, only the taxpayer 
which makes payments under the re­
search contract and on whose behalf 
the research is conducted can claim 
the credit as to those expenditures; the 
research firm, university, or other per­
son which conducts the research on 
behalf of the taxpayer cannot claim any 
credit for its expenditures in perform­
ing the contract.”
Therefore, only Corp. X is qualified to 
take the credit. However, E-N would still 
be able to benefit from R&D expense 
deductions allowed under Section 174.
Section 174—Research and 
Experimental Expenditures
Section 174 allows a taxpayer to treat 
as expenses any research or experi­
mental expenditures paid or incurred in 
connection with his trade or business. 
(Sec. 174(a)) Regulation 1.1.74-2 states;
‘‘The term ‘research or experimental 
expenditures, ’ as used in section 174, 
means expenditures incurred in con­
nection with the taxpayer’s trade or 
business which represent research and 
development costs in the experimental 
or laboratory sense. The term includes 
generally all such costs incident to the 
development of an experimental or pilot 
model, a plant process, a product, a 
formula, an invention, or similar prop­
erty, and the improvement of already 
existing property of the type mentioned.
The term does not include expenditures 
such as those for the ordinary testing 
or inspection of materials or products 
for quality control or those for efficiency 
surveys, management studies, con­
sumer surveys, advertising, or promo­
tions. However, the term includes the 
costs of obtaining a patent, such as at­
torneys’ fees expended in making and 
perfecting a patent application. On the 
other hand, the term does not include 
the costs of acquiring another’s patent, 
model, production or process, nor does 
it include expenditures paid or incurred 
for research in connection with literary, 
historical, or similar projects.
The provisions of this section apply 
not only to costs paid or incurred by 
the taxpayer for research or experi­
mentation undertaken directly by him 
but also to expenditures paid or in­
curred for research or experimenta­
tion carried on in his behalf by 
another person or organization (such 
as a research institute, foundation, 
engineering company, or similar 
contractor). ”
Thus, it is permissable for both Corp. 
X and Partnership E-N to deduct as ex­
penses the allowable “research or ex­
perimental expenditures”. For X, this 
would be the amounts paid to E-N. For 
E-N, this would be the costs incurred 
in performing R&D for Corp. X, which 
would offset the income received from 
X.
After substantial R&D expenses, 
Partnership E-N hopes to have devel­
oped plans for a new or improved prod­
uct which can be patented. They also 
hope that Corp. X will want to purchase 
the patent.
In considering the tax consequences 
of the sale of the patent, it is necessary 
to look at Section 1235 of the 1954 
Code.
Section 1235—Sale or Exchange of 
Patents
Section 1235(a) states that the sale 
of a patent qualifies for capital gains 
treatment if:
(1) all substantial rights to the pa­
tent are transferred,
(2) by a holder of the patent,
(3) to an unrelated party.
Reg. 1.1235-2(b) defines “all sub­
stantial rights” as follows:
‘‘The term ‘all substantial rights to a 
patent’ means all rights (whether or 
not then held by the grantor) which 
are of value at the time the rights to 
the patent (or an undivided interest 
therein) are transferred. The term ‘all 
substantial rights to a patent’ does 
not include a grant of rights to a 
patent—
(i) Which is limited geographically 
within the country of issuance;
(ii) Which is limited in duration by 
the terms of the agreement to a 
period less than the remaining life of 
the patent;
(Hi) Which grants rights to the 
grantee, in fields of use within trades 
or industries which are less than all 
the rights covered by the patent, 
which exist and have value at the 
time of the grant;
(iv) Which grants to the grantee 
less than all the claims or inventions 
covered by the patent, which exist 
and have value at the time of the 
grant, 
The circumstances of the whole 
transaction, rather than the particular 
terminology used in the instrument of 
transfer, shall be considered in deter­
mining whether or not all substantial 
rights to a patent are transferred in a 
transaction.
(2) Rights which are not con­
sidered substantial for purposes of 
section 1235 may be retained by the 
holder. Examples of such rights are:
(i) The retention by the transferor of 
legal title for the purpose of securing 
performance or payment by the 
transferee in a transaction involving 
transfer of an exclusive license to 
manufacture, use, and sell for the life 
of the patent:
(ii) The retention by the transferor 
of rights in the property which are not 
inconsistent with the passage of 
ownership, such as the retention of 
a security interest (such as a vendor’s 
lien), or a reservation in the nature of 
a condition subsequent (such as a 
provision for forfeiture on account of 
nonperformance).
(3) Examples of rights which may 
or may not be substantial, depending 
upon the circumstances of the whole 
transaction in which rights to a patent 
are transferred, are:
(i) The retention by the transferor of 
an absolute right to prohibit sub­
licensing or subassignment by the 
transferee;
(ii) The failure to convey to the 
transferee the right to use or to sell 
the patent property.
(4) The retention of a right to ter­
minate the transfer at will is the reten­
tion of a substantial right for the pur­
poses of section 1235.”
The term “holder” as defined by 
Reg. 1.1235-2(d) is any individual who 
invented the patent property. In the 
case of a partnership, each member of 
the partnership is a holder.
Partnership E-N will have no prob­
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lems in satisfying the first two re­
quirements of Sec. 1235. However, the 
last requirement of Sec. 1235, that the 
sale must be to an unrelated party, will 
disqualify the sale from receiving 
capital gains treatment under Sec. 
1235. Partner E is a 78 percent stock­
holder of Corp. X and Reg. 1.1235-2(f) 
states that;
“If, subsequent to September 2, 
1958, a holder transfers all his sub­
stantial rights to a patent to a corpora­
tion in which he owns 25 percent or 
more in value of the outstanding 
stock, he is considered as transfer­
ring such rights to a related person 
for the purpose of section 1235. ’’ 
Therefore, according to Sec. 1235, 
upon sale of the patent to Corp. X, 
Partner N would receive capital gains 
treatment on his one half of the patent. 
Partner E would be required to claim 
ordinary income for the sale proceeds 
of his one half.
However, Partner E has another op­
tion available for obtaining capital gain 
treatment. The Regulations state that 
“a transfer by a holder to a related per­
son is not governed by section 1235” 
and is determined under other provi­
sions of the internal revenue laws. 
(Reg. 1.1235-2(f)) The IRS has reaf­
firmed this position; it states in 
Revenue Ruling 69-4822 that,
“The mere fact that a patent 
transfer for contingent amounts does 
not qualify for long-term capital gains 
treatment under Code Sec. 1235 will 
not prevent it from qualifying for such 
treatment under other provisions of 
the Code. ”
Therefore, because the patent is a 
depreciable capital asset, the sale can 
qualify for capital gains treatment 
under Sec. 1221 as long as the provi­
sions of Sec. 1239 do not apply and 
cause ordinary income treatment of 
the gain.
Section 1239—Sales Between Related 
Parties
For sales of depreciable property, 
code section 1239(b) states that any 
gain should be treated as ordinary in­
come if the sale is between a taxpayer 
and his 80 percent owned entity.
Section 1239(c) defines an 80 per­
cent owned entity as a corporation in 
which the taxpayer owns 80 percent or 
more in value of the outstanding stock. 
For the purposes of this section fami­
ly attribution rules apply only to the in­
dividual and his or her spouse.
It would appear from this definition 
that the sale of the patent by E-N to X 
would not fall under Sec. 1239 and that 
Partner E would be able to receive 
capital gains treatment for his portion 
of the gain on the sale.
However, in applying the 80 percent 
test, the Court of Appeals for the Fifth 
Circuit has interpreted the words “in 
value” to mean more than merely the 
number of shares or the voting power. 
In “C.L. Parker”3, the court found that 
even though Parker owned exactly 80 
percent of the outstanding stocks and 
Eaves owned exactly 20 percent that 
Parker owned more than 80 percent in 
value of the corporation’s outstanding 
stock.
Parker had sold depreciable assets 
to his 80 percent owned corporation 
and had elected to treat the sale as a 
capital transaction. The court noted 
that, because Parker owned exactly 80 
percent of the outstanding stock,
“if any fact can be found which 
shows that the value per share of 
Parker’s stock exceeded by any 
amount, no matter how small, the 
value per share of Eaves’s, then 
Parker, owned more than 80 percent 
in value of the outstanding stock.’’3
The court then determined that, 
because Parker owned the controlling 
interest of the corporation, his stock 
represented more than 80 percent in 
value of the corporation.
“Parker controlled without possi­
bility of challenge the entire operation 
from the smallest detail to the largest. 
He exercised so much power that the 
corporation was his alter ego, or his 
slave. This is the situation at which 
1239 aims.
Any purchaser of Eaves’ stock 
would not be buying any degree of 
control over the corporation. The 
voting power which technically in­
hered in Eaves’s stock was in reality 
worthless; Parker owned all of the 
real voting stock.
We hold that this disability which 
inhered in Eaves’s stock reduced its 
value per share below that of Parker’s 
stock as a matter of law. ”3
Therefore, the sale of the depreci­
able assets was ruled to fall under Sec­
tion 1239 and the gain was taxed as 
ordinary income.
The court has upheld this 80 percent 
in value decision in “E.L. Childers”4 in 
1974 and again in “H.P. Dahlgren”5 in 
1977.
In the Dahlgren case, Dahlgren sold 
his interest in a patent to a corporation 
in which he owned 79.5 percent of the 
outstanding stock. He treated the 
transaction as a sale of a capital asset 
and took capital gains treatment on his 
tax return. A U.S. District Court first 
found that Dahlgren’s treatment of the 
sale was correct based on his 79.5 per­
cent ownership of the outstanding 
stock. The U.S. Court of Appeals at 
New Orleans reversed and remanded 
the decision of the U.S. District Court. 
In its conclusion, the U.S. Court of Ap­
peals stated that;
“the trial court erred in not charging 
the jury on the important issue pre­
sented by the “Parker principle” 
touching on the inherent added value 
increment in a controlling block of 
stock. ”5
In “E.L. Parker”3 the courts em­
phasized the importance of Section 
1239.
“Section 1239 prevents capital 
gain treatment of a ‘sale or exchange’ 
of depreciable property to a con­
trolled corporation or a spouse. With­
out this section a taxpayer who had 
property which had been depreciated 
to a low basis could sell that property 
to a controlled corporation or spouse 
and pay only capital gains rates on 
the gain. The transferee (who is virtu­
ally identical to the transferor in the 
proscribed area) could then redepre­
ciate the property, using the sale 
price as a new basis. The deprecia­
tion, of course, would be deducted 
from ordinary income. Section 1239 
renders such a scheme profitless by 
taxing the gain on the transfer at or­
dinary rather than capital rates.’’3
In light of these court decisions, it is 
likely that the sale of the patent by E- 
N to X would come under Section 1239 
for Partner E by virtue of his 78 per­
cent ownership of the outstanding 
stock carrying a value of 80 percent or 
more in the corporation.
One way to avoid this would be for 
E to sell to one of his children a por­
tion of his stock so that the value of the 
outstanding stock owned by E would 
be less than 80 percent. This is possi­
ble because after October 19, 1980, 
the family attribution rules apply only 
to husbands and wives.6 However, it 
would be difficult to determine how 
much he should sell in order to 
decrease the value of his ownership 
value below 80 percent. Also, share­
holder E has expressed that he does 
not wish to give up any of his stock 
ownership if there is any other way that 
he may achieve capital gains treat­
ment on the sale of the patent.
There is one other possibility for 
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escape from falling under Section 
1239. That is for Partnership E-N not 
to patent the invention before sale to 
Corp. X. An unpatented invention is 
not a depreciable asset because of an 
indeterminate useful life and therefore 
does not fall under Section 1239. It 
also does not come under Section 
1235. Therefore, the seller can be a 
100 percent owner of the corporation 
to which he is selling his unpatented 
invention and receive capital gains 
treatment on the sale. Also, after ob­
taining the patent, Corp. X will be able 
to depreciate the cost of purchasing 
the invention plus any costs incurred 
in obtaining the patent.7
However, Partnership E-N must be 
careful, if a patent application has 
been made, to sell the patent applica­
tion to Corp. X before it is evident that 
the patent will be allowed.
In “Estate of Stahl v. Commis­
sioner” (1971)8 the taxpayer sold to his 
wholly-owned corporation various (1) 
patents, (2) patent applications to 
which notices of allowance or indica­
tions of allowability had been received 
prior to transfer, and (3) patent applica­
tions which had, prior to transfer, been 
rejected by the Patent Office. The 
court ruled that the patent applications 
which were allowed or which had in­
dications of allowability from the Patent 
Office ((2) above) had “matured” into 
depreciable assets and thus, along 
with the patents, were subject to Sec­
tion 1239 and the gains were taxed as 
ordinary income. However, the patent 
applications which were rejected ((3) 
above) were not depreciable and 
therefore the gains were taxed at 
capital gain rates.
In “L.J. Chu”9 the following facts 
were presented:
(1) On June 26, 1956, Chu filed an 
application with the U.S. Patent 
Office seeking a patent on a new 
antenna. The application involv­
ed claims 1-18.
(2) On July 5, 1957, the Patent Of­
fice disallowed claims 1-13 but 
indicated allowability of claims 
14-18.
(3) On December 9, 1957, Chu filed 
an Amendment A.
(4) The Patent Office responded 
that in addition to claims 14-18, 
claim 12 also appeared 
allowable.
(5) On September 14, 1959, 
Amendment B was filed.
(6) The Patent Office adhered to its 
previous position.
(7) On December 18, 1959, Chu 
sold his interest in the patent ap­
plication to Chu Associates, Inc. 
Chu owned 80% of the out­
standing stock on that date.
(8) On March 8, 1960, Chu Asso­
ciates, Inc. filed Amendment C.
(9) On September 7, 1960 the Pa­
tent Office allowed all 18 claims.
The Court ruled that the patent ap­
plications were not depreciable assets 
and therefore escaped Section 1239. 
The court stated that;
“we must not forget that not every pa­
tent application is ultimately ap­
proved. Consequently, were we to 
apply the interpretation of 1239 
sought by the government, the inven­
tor who has the misfortune to trans­
fer a patent application that is 
subsequently disapproved would 
face the worst of both possible 
worlds: he would pay ordinary in­
come rates on his initial gain from the 
transfer, while his controlled corpora­
tion would never be able to take any 
depreciable deduction against or­
dinary income. It would be entirely 
rational, therefore, for Congress to 
conclude that 1239 should apply only 
in those instances where the dangers 
of tax abuse were most acute (i.e. the 
transfer to a controlled corporation of 
depreciable property), while denying 
1239 treatment to situations where 
unwarranted tax results might 
occur.”9
Conclusion
In order for Corporation X and Part­
nership E-N to obtain the maximum 
benefits from the tax code concerning 
Research and Development expendi­
tures, they should follow the plan out-
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lined below:
I. Form Partnership E-N to conduct 
R&D for Corp. X.
A. Corp. X will be eligible to take 
the credit for Research Activities 
under Sec. 44F for 65 percent of 
amounts paid to E-N. E-N is not 
eligible.
1. Be certain to have a written 
contract between X & E-N.
B. Corp. X and Partnership E-N 
may both deduct R&D expendi­
tures under Sec. 174.
1. For X, this is the amount paid 
to E-N.
2. For E-N, this is the amount 
expended in carrying on 
R&D.
II. Sale of Invention by Partnership E- 
N to Corp. X.
A. Sale should be completed before 
an indication of allowability of pa­
tent is received.
1. The unpatented invention is 
not a depreciable asset and 
Section 1239 will not apply.
2. The gain on the sale will be 
capital gains to Partners E & 
N.
B. If patent is obtained;
1. Partner N will still receive 
capital gains treatment under 
Sec. 1235.
2. Partner E will have to claim 
the gain as ordinary income 
because he will not meet the 
requirements of Sec. 1235. 
He is selling the patent to a 
related party.
a. Partner E could sell a por­
tion of his stock to one of 
his children and meet the 
requirements of Sec. 
1235.
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